WDNA
WisdomTree BioRevolution ETF
WisdomTree BioRevolution USD
NAV as of
4 Week: 16.50 - 17.64
52 Week: 16.00 - 20.82
Latest Closing Price
16.73
Premium / Discount
0.02
Expense Ratio
0.45%
Investment Objective
The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
Main Fund Characteristics
Performance
Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
---|---|---|---|
YTD | -3.99 | 1.21 | -3.30 |
1 Day | -0.40 | 0.00 | 0.00 |
1 Week | -1.24 | 2.65 | -0.47 |
1 Month | -3.08 | 5.96 | -0.52 |
3 Months | -1.78 | 9.73 | -0.18 |
6 Months | -3.27 | 17.04 | -0.19 |
1 Year | -16.96 | 27.59 | -0.61 |
2 Years | 0.00 | 0.00 | 0.00 |
3 Years | 0.00 | 0.00 | 0.00 |
5 Years | 0.00 | 0.00 | 0.00 |
10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -26.0556 |
Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 80.0000 |
Dividend Frequency
Lastest Dividend
Ex Date | Payment Date | Dividend Payout per unit |
---|---|---|
22/12/2022 | 28/12/2022 | 0.0653 |
26/12/2021 | 29/12/2021 | 0.0246 |
Portfolio Data
Total Number of Holdings: 99
Number of Bond Holdings: 0
Number of Equity Holdings: 99
Total Market Value: 2,654,994
Portfolio Composition
Top 10 Holdings
% Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
---|---|---|---|---|---|
1 | AstraZeneca PLC ADR | 2.2622 | 1,416 | 0 | 82,425 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
Size | % of portfolio |
---|---|
Giant | 18.30 |
Large | 24.26 |
Medium | 31.76 |
Small | 11.47 |
Micro | 13.95 |
Equity Style Box Breakdown
0 | 0 | 0 | Large |
0 | 0 | 0 | Mid |
0 | 0 | 0 | Small |
Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
18.4702
Price/Book*
2.5991
Price/Sales*
2.2132
Price/Cash Flow*
11.3862
Dividend Yield*
1.0853
Growth Measures
Long-Term Earnings
7.5567
Historical Earnings
27.4076
Sales Growth
10.9424
Cash-Flow Growth
7.8594
Book-Value Growth
5.0339
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
Detail | Value |
---|---|
Average Effective Duration | 0 |
Average Effective Maturity (Years)* | 0 |
Average Credit Quality | 0 |
Average Weighted Coupon* | 0 |
Average Weighted Price* | 0 |
Bond Style Box Breakdown
0 | 0 | 0 | High | Quality |
0 | 0 | 0 | Med | |
0 | 0 | 0 | Low | |
Ltd | Mod | Ext | ||
Interest-Rate Sensitivity |
Credit Quality
Type | % Bonds |
---|---|
N.A |
Bond Sector
Bond Maturity
% Bonds | |
---|---|
N.A |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.